Last reviewed · How we verify
Collagen matrix graft
The collagen matrix graft, developed by São Paulo State University, is a marketed product with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Collagen matrix graft |
|---|---|
| Also known as | heterogenous graft |
| Sponsor | São Paulo State University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators. (PHASE2)
- Intervascular Post-Market Clinical Follow-Up (PMCF) Registry
- Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT (NA)
- A Novel Volume Stable Matrix for Gingival Recession Coverage at Teeth (NA)
- Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix (NA)
- FIBERGRAFT Aeridyan Posterolateral Fusion Study (NA)
- Acellular Collagen Matrix as a Tool to Obtain Wound Closure Following a Guided Bone Regeneration Procedure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Collagen matrix graft CI brief — competitive landscape report
- Collagen matrix graft updates RSS · CI watch RSS
- São Paulo State University portfolio CI